MX350075B - Hidroxido de carbonato de lantano, oxicarbonato de lantano y metodos para su fabricacion y uso. - Google Patents
Hidroxido de carbonato de lantano, oxicarbonato de lantano y metodos para su fabricacion y uso.Info
- Publication number
- MX350075B MX350075B MX2012013065A MX2012013065A MX350075B MX 350075 B MX350075 B MX 350075B MX 2012013065 A MX2012013065 A MX 2012013065A MX 2012013065 A MX2012013065 A MX 2012013065A MX 350075 B MX350075 B MX 350075B
- Authority
- MX
- Mexico
- Prior art keywords
- lantan
- oxycharbonate
- manufacture
- methods
- carbonate hydroxide
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/244—Lanthanides; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2068—Compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01F—COMPOUNDS OF THE METALS BERYLLIUM, MAGNESIUM, ALUMINIUM, CALCIUM, STRONTIUM, BARIUM, RADIUM, THORIUM, OR OF THE RARE-EARTH METALS
- C01F17/00—Compounds of rare earth metals
- C01F17/20—Compounds containing only rare earth metals as the metal element
- C01F17/247—Carbonates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2002/00—Crystal-structural characteristics
- C01P2002/70—Crystal-structural characteristics defined by measured X-ray, neutron or electron diffraction data
- C01P2002/72—Crystal-structural characteristics defined by measured X-ray, neutron or electron diffraction data by d-values or two theta-values, e.g. as X-ray diagram
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2004/00—Particle morphology
- C01P2004/01—Particle morphology depicted by an image
- C01P2004/03—Particle morphology depicted by an image obtained by SEM
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2004/00—Particle morphology
- C01P2004/60—Particles characterised by their size
- C01P2004/61—Micrometer sized, i.e. from 1-100 micrometer
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2006/00—Physical properties of inorganic compounds
- C01P2006/10—Solid density
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2006/00—Physical properties of inorganic compounds
- C01P2006/11—Powder tap density
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2006/00—Physical properties of inorganic compounds
- C01P2006/12—Surface area
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2006/00—Physical properties of inorganic compounds
- C01P2006/14—Pore volume
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2006/00—Physical properties of inorganic compounds
- C01P2006/80—Compositional purity
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dispersion Chemistry (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Geology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Botany (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Compounds Of Alkaline-Earth Elements, Aluminum Or Rare-Earth Metals (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33388710P | 2010-05-12 | 2010-05-12 | |
| PCT/US2011/036317 WO2011143475A1 (en) | 2010-05-12 | 2011-05-12 | Lanthanum carbonate hydroxide, lanthanum oxycarbonate and methods of their manufacture and use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2012013065A MX2012013065A (es) | 2013-03-21 |
| MX350075B true MX350075B (es) | 2017-08-25 |
Family
ID=44279001
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012013065A MX350075B (es) | 2010-05-12 | 2011-05-12 | Hidroxido de carbonato de lantano, oxicarbonato de lantano y metodos para su fabricacion y uso. |
Country Status (16)
| Country | Link |
|---|---|
| US (5) | US8961917B2 (enExample) |
| EP (2) | EP3848040A1 (enExample) |
| JP (4) | JP5993368B2 (enExample) |
| KR (2) | KR101940207B1 (enExample) |
| CN (1) | CN103037870B (enExample) |
| AR (2) | AR081395A1 (enExample) |
| AU (1) | AU2011252983C1 (enExample) |
| BR (1) | BR112012028629B8 (enExample) |
| CA (2) | CA3224506A1 (enExample) |
| ES (1) | ES2871021T3 (enExample) |
| IL (1) | IL222824B (enExample) |
| MX (1) | MX350075B (enExample) |
| RU (1) | RU2570007C2 (enExample) |
| TW (1) | TWI446916B (enExample) |
| WO (1) | WO2011143475A1 (enExample) |
| ZA (1) | ZA201209322B (enExample) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2011252983C1 (en) * | 2010-05-12 | 2015-02-19 | Unicycive Therapeutics, Inc. | Lanthanum carbonate hydroxide, lanthanum oxycarbonate and methods of their manufacture and use |
| US9575059B2 (en) | 2012-06-05 | 2017-02-21 | 3M Innovative Properties Company | Lanthanum-based concentration agents for microorganisms |
| CA2876689C (en) | 2012-06-13 | 2022-04-26 | Incyte Corporation | Substituted tricyclic compounds as fgfr inhibitors |
| PH12015502383B1 (en) | 2013-04-19 | 2023-02-03 | Incyte Holdings Corp | Bicyclic heterocycles as fgfr inhibitors |
| CN104129810A (zh) * | 2013-05-02 | 2014-11-05 | 南京大学 | 纯单斜晶相的刺球状碳酸氧镧(La2O2CO3)三维多级结构的制备 |
| CN104592994B (zh) * | 2015-01-14 | 2018-01-02 | 惠州学院 | 一种三角枝状铕掺杂羟基碳酸镧红色荧光粉的制备方法 |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| CA2976790C (en) | 2015-02-20 | 2024-02-27 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| JP6093829B1 (ja) * | 2015-10-02 | 2017-03-08 | バイエル薬品株式会社 | ランタン化合物を含む医薬組成物 |
| CN105749892B (zh) * | 2016-05-16 | 2018-02-02 | 哈尔滨工业大学 | 一种针对水体除磷的海胆状微球碳酸氧镧吸附剂的制备方法 |
| CN109314212B (zh) * | 2016-06-24 | 2022-02-08 | 日本碍子株式会社 | 包含层状双氢氧化物的功能层及复合材料 |
| CN107188215A (zh) * | 2017-05-24 | 2017-09-22 | 中国北方稀土（集团）高科技股份有限公司 | 碳酸稀土连续沉淀生产过程中自动调节反应终点的方法 |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| RU2657755C1 (ru) * | 2017-07-10 | 2018-06-15 | Александр Александрович Кролевец | Способ получения нанокапсул солей лантаноидов в каррагинане |
| US11865509B2 (en) | 2018-01-04 | 2024-01-09 | Asahi Kasei Kabushiki Kaisha | Porous molding |
| RS66310B1 (sr) | 2018-05-04 | 2025-01-31 | Incyte Corp | Čvrsti oblici inhibitora fgfr i procesi za njegovu pripremu |
| KR102956194B1 (ko) | 2018-05-04 | 2026-04-23 | 인사이트 코포레이션 | Fgfr 억제제의 염 |
| CN111587372B (zh) * | 2018-07-13 | 2023-09-19 | 富士电机株式会社 | 二氧化碳气体传感器 |
| JP7506892B2 (ja) * | 2018-08-21 | 2024-06-27 | 東和薬品株式会社 | 化合物の特定形状の結晶及びその製造方法 |
| JP2020099866A (ja) * | 2018-12-21 | 2020-07-02 | 旭化成株式会社 | 多孔性成形体 |
| RU2693176C1 (ru) * | 2018-12-28 | 2019-07-01 | Общество С Ограниченной Ответственностью "Лаборатория Инновационных Технологий" | Способ получения карбонатов редкоземельных элементов |
| CN109490464A (zh) * | 2019-01-24 | 2019-03-19 | 内蒙古医科大学 | 一种基于离子色谱技术测定稀土药物中镧元素含量的方法 |
| WO2020185532A1 (en) | 2019-03-08 | 2020-09-17 | Incyte Corporation | Methods of treating cancer with an fgfr inhibitor |
| WO2021007269A1 (en) | 2019-07-09 | 2021-01-14 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| US12122767B2 (en) | 2019-10-01 | 2024-10-22 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| GEP20247679B (en) | 2019-10-14 | 2024-10-10 | Incyte Corp | Bicyclic heterocycles as fgfr inhibitors |
| US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| MX2022006691A (es) | 2019-12-04 | 2022-09-19 | Incyte Corp | Derivados de un inhibidor de receptores del factor de crecimiento de fibroblastos (fgfr). |
| WO2021113479A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| CN113029978A (zh) * | 2019-12-25 | 2021-06-25 | 远大生命科学(辽宁)有限公司 | 一种检测含镧试剂的磷结合能力的方法 |
| US12012409B2 (en) | 2020-01-15 | 2024-06-18 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| CN113019305B (zh) * | 2021-03-03 | 2021-10-15 | 重庆三峡学院 | 多孔碱式碳酸镧磷酸盐吸附剂的制备及其应用 |
| EP4323405A1 (en) | 2021-04-12 | 2024-02-21 | Incyte Corporation | Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent |
| CN113311100A (zh) * | 2021-05-27 | 2021-08-27 | 南京诺亚药业有限公司 | 一种碳酸镧制剂中的镧含量的测定方法 |
| CA3220274A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| TW202313610A (zh) | 2021-06-09 | 2023-04-01 | 美商英塞特公司 | 作為ｆｇｆｒ抑制劑之三環雜環 |
| CN115487839B (zh) * | 2021-06-17 | 2024-03-26 | 中国石油化工股份有限公司 | 片状催化剂及其制备方法和应用 |
| CN114749182A (zh) * | 2022-03-29 | 2022-07-15 | 中国科学院兰州化学物理研究所 | 一种用于甲烷干重整的镍-氧化镧催化剂及其制备方法 |
| CN116924449B (zh) * | 2022-03-29 | 2025-12-09 | 包头稀土研究院 | 碱式碳酸镧颗粒及其制备方法 |
| CN116924450B (zh) * | 2022-03-29 | 2025-09-30 | 包头稀土研究院 | 用氯化稀土料液制备碱式碳酸稀土的方法 |
| US20260014083A1 (en) * | 2022-07-01 | 2026-01-15 | Amgmt | Orally Administrable Pharmaceutical Dosage Form Comprising Lanthanum and Its Use in a Method Of Treatment of Hyperoxaluria |
| CN116809015A (zh) * | 2023-04-03 | 2023-09-29 | 中国市政工程中南设计研究总院有限公司 | 一种粘土-碳酸镧复合材料及其制备方法和应用 |
| CN121221637A (zh) * | 2025-11-27 | 2025-12-30 | 南昌大学第一附属医院 | 碳酸镧在制备抗肝硬化和抑制肝脏炎症药物中的应用 |
Family Cites Families (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3768989A (en) | 1968-08-19 | 1973-10-30 | N Goetzinger | Process for the preparation of a rare earth oxide polishing composition |
| US3692671A (en) | 1970-10-01 | 1972-09-19 | North American Rockwell | Rare earth ion removal from waste water |
| US3922333A (en) | 1973-06-04 | 1975-11-25 | Us Air Force | Process for preparing mullite powder and fabrication of structural bodies therefrom |
| US3922331A (en) | 1973-11-14 | 1975-11-25 | Us Interior | Preparation of microporous rare-earth oxyhalides |
| US4240048A (en) | 1978-12-15 | 1980-12-16 | E. I. Du Pont De Nemours & Co. | Nonlinear optical device |
| ATE5845T1 (de) | 1980-11-14 | 1984-02-15 | Rudolf Schanze | Fuer menschen und tiere geeignetes, spurenelemente enthaltendes konzentrat, ein verfahren zu seiner herstellung und seine verwendung. |
| US4462970A (en) | 1981-08-19 | 1984-07-31 | Hughes Aircraft Company | Process for preparation of water-free oxychloride material |
| US4497785A (en) | 1983-11-18 | 1985-02-05 | Union Oil Company Of California | Production of rare earth compounds |
| JPS60206448A (ja) | 1984-03-29 | 1985-10-18 | Nissan Motor Co Ltd | 排ガス浄化用触媒担体 |
| JPS60226414A (ja) | 1984-04-20 | 1985-11-11 | Hitachi Ltd | ランタン・アルミナ系複合酸化物の製造法 |
| JPS614529A (ja) | 1984-06-15 | 1986-01-10 | Asahi Chem Ind Co Ltd | リン酸イオンの吸着剤 |
| AU601998B2 (en) | 1985-07-11 | 1990-09-27 | Rhone-Poulenc Specialites Chimiques | Oxygenated rare earth derivatives |
| US5782792A (en) | 1986-11-21 | 1998-07-21 | Cypress Bioscience, Inc. | Method for treatment of rheumatoid arthritis |
| US4919902A (en) | 1987-09-30 | 1990-04-24 | Allied-Signal Inc. | Catalyst for treatment of exhaust gases from internal combustion engines |
| FR2623797B2 (fr) | 1987-08-05 | 1990-05-04 | Inst Francais Du Petrole | Procede de conversion du methane en hydrocarbures superieurs |
| US5234957A (en) | 1991-02-27 | 1993-08-10 | Noven Pharmaceuticals, Inc. | Compositions and methods for topical administration of pharmaceutically active agents |
| FR2634398B1 (fr) | 1988-06-29 | 1990-09-07 | Elf Aquitaine | Procede de preparation d'un catalyseur apte a promouvoir la conversion oxydante du methane en hydrocarbures superieurs |
| GB9201857D0 (en) | 1992-01-29 | 1992-03-18 | Smithkline Beecham Plc | Novel compound |
| US5407560A (en) | 1992-03-16 | 1995-04-18 | Japan Energy Corporation | Process for manufacturing petroleum cokes and cracked oil from heavy petroleum oil |
| EP0604919A1 (en) | 1992-12-28 | 1994-07-06 | Ishihara Sangyo Kaisha, Ltd. | Deodorant |
| WO1994019286A1 (en) | 1993-02-24 | 1994-09-01 | Dudley John Mills | Treatment of swimming pool water |
| US5667775A (en) | 1993-08-11 | 1997-09-16 | Geltex Pharmaceuticals, Inc. | Phosphate-binding polymers for oral administration |
| JPH0810610A (ja) | 1994-07-05 | 1996-01-16 | Ishihara Sangyo Kaisha Ltd | リン吸着剤 |
| GB9506126D0 (en) * | 1995-03-25 | 1995-05-10 | Johnson Matthey Plc | Pharmaceutical composition and method |
| US6376479B1 (en) | 1995-04-03 | 2002-04-23 | Bone Care International, Inc. | Method for treating and preventing hyperparathyroidism |
| US20020183288A1 (en) | 1995-04-03 | 2002-12-05 | Bone Care International, Inc. | Method for treating and preventing hyperparathyroidism |
| GB9611437D0 (en) | 1995-08-03 | 1996-08-07 | Secr Defence | Biomaterial |
| JP2843909B2 (ja) | 1996-05-27 | 1999-01-06 | 科学技術庁無機材質研究所長 | 酸化イットリウム透明焼結体の製造方法 |
| JP3081910B2 (ja) | 1997-08-07 | 2000-08-28 | 工業技術院長 | ヒ素（ｖ）イオンの除去方法 |
| GB9720061D0 (en) | 1997-09-19 | 1997-11-19 | Crosfield Joseph & Sons | Metal compounds as phosphate binders |
| US5843477A (en) | 1997-09-30 | 1998-12-01 | Bayer Corporation | Lubricants for use in tabletting |
| DK1067910T3 (da) | 1998-04-03 | 2004-10-04 | Egalet As | Komposition med styret afgivelse |
| US6197201B1 (en) | 1998-07-29 | 2001-03-06 | The Board Of Regents Of The University & Community College System Of Nevada | Process for removal and stabilization of arsenic and selenium from aqueous streams and slurries |
| US6312604B1 (en) | 1998-10-23 | 2001-11-06 | Zodiac Pool Care, Inc. | Lanthanide halide water treatment compositions and methods |
| DE60029628T2 (de) | 1999-12-22 | 2007-07-26 | Wisconsin Alumni Research Foundation, Madison | Calciumformiat als diätzusatz |
| US6338800B1 (en) | 2000-02-22 | 2002-01-15 | Natural Chemistry, Inc. | Methods and compositions using lanthanum for removing phosphates from water |
| US6521647B2 (en) | 2000-04-04 | 2003-02-18 | Pfizer Inc. | Treatment of renal disorders |
| GB0015745D0 (en) | 2000-06-27 | 2000-08-16 | Shire Holdings Ag | Treatment of bone diseases |
| JP3407039B2 (ja) | 2000-07-10 | 2003-05-19 | 独立行政法人産業技術総合研究所 | ヒ素汚染土壌洗浄剤並びにヒ素汚染土壌安定化剤及びこれらをを用いたヒ素汚染土壌修復方法 |
| FR2811571B1 (fr) | 2000-07-11 | 2002-10-11 | Flamel Tech Sa | Composition pharmaceutique orale, permettant la liberation controlee et l'absorption prolongee d'un principe actif |
| US6403523B1 (en) | 2000-09-18 | 2002-06-11 | Union Carbide Chemicals & Plastics Technology Corporation | Catalysts for the oxidative dehydrogenation of hydrocarbons |
| FR2820134A1 (fr) | 2001-01-29 | 2002-08-02 | Rhodia Elect & Catalysis | Oxychlorure de terre rare a surface specifique elevee, ses procedes de preparation et son utilisation comme catalyseur |
| US6849609B2 (en) | 2001-04-10 | 2005-02-01 | James U. Morrison | Method and composition for controlled release acarbose formulations |
| JP4515030B2 (ja) | 2001-04-23 | 2010-07-28 | アノーメッド インコーポレイティド | 腎臓結石疾患の予防のための希土類化合物の使用 |
| MXPA04002973A (es) | 2001-09-28 | 2005-06-20 | Johnson & Johnson | Formas de dosis de liberacion modificada. |
| US7119120B2 (en) | 2001-12-26 | 2006-10-10 | Genzyme Corporation | Phosphate transport inhibitors |
| WO2003094933A2 (en) | 2002-05-08 | 2003-11-20 | Shire Holding Ag | Use of lanthanum for the treatment of hypercalcemia and bone metastasis |
| US20040161474A1 (en) | 2002-05-24 | 2004-08-19 | Moerck Rudi E. | Rare earth metal compounds methods of making, and methods of using the same |
| US20060083791A1 (en) | 2002-05-24 | 2006-04-20 | Moerck Rudi E | Rare earth metal compounds methods of making, and methods of using the same |
| CN100526219C (zh) | 2002-08-14 | 2009-08-12 | 爱尔达纳米公司 | 稀土金属化合物、其制造方法及其使用方法 |
| MY148805A (en) | 2002-10-16 | 2013-05-31 | Takeda Pharmaceutical | Controlled release preparation |
| WO2004050558A2 (en) | 2002-12-02 | 2004-06-17 | Altair Nanomaterials Inc. | Rare earth compositions and structures for removing phosphates from water |
| JP4128906B2 (ja) * | 2003-05-15 | 2008-07-30 | 三井金属鉱業株式会社 | セリウム系研摩材及びセリウム系研摩材の製造方法 |
| DK2792363T3 (da) * | 2003-08-26 | 2016-09-26 | Shire Biopharmaceuticals Holdings Ireland Ltd | Farmaceutisk formulering, der omfatter lanthanforbindelser |
| US7381428B2 (en) | 2003-08-26 | 2008-06-03 | Shire International Licensing B.V. | Stabilized lanthanum carbonate compositions |
| JP4834953B2 (ja) | 2003-10-31 | 2011-12-14 | 富士ゼロックス株式会社 | 脂肪族ポリケトン類ポリマー及び脂肪族ポリケトン類ポリマー含有組成物の製造方法 |
| US7459502B2 (en) | 2003-11-03 | 2008-12-02 | Ilypsa, Inc. | Pharmaceutical compositions comprising crosslinked polyamine polymers |
| US20050182011A1 (en) | 2003-11-13 | 2005-08-18 | Eric Olson | Inhibition of TRP channels as a treatment for cardiac hypertrophy and heart failure |
| CN1557982A (zh) | 2004-01-19 | 2004-12-29 | 太原理工大学 | 细化阻燃复合剂及其制备方法 |
| MX2007001114A (es) | 2004-07-27 | 2007-07-11 | Shire Pharmaceuticals Inc | Metodo para tratar hiperfosfatemia usando hidroxicarbonato de lantano. |
| US20060134225A1 (en) | 2004-10-15 | 2006-06-22 | Moerck Rudi E | Phosphate binder with reduced pill burden |
| US20060177415A1 (en) | 2004-11-01 | 2006-08-10 | Burke Steven K | Once a day formulation for phosphate binders |
| EP1698233A1 (en) | 2005-03-01 | 2006-09-06 | Bayer HealthCare AG | Reduction of digestibility of phosphorus in animal nutrition |
| JP2009504423A (ja) | 2005-08-11 | 2009-02-05 | イノヴァライト インコーポレイテッド | 安定にパッシベートされたｉｖ族半導体ナノ粒子、並びにその製造方法及びその組成物 |
| WO2007022445A2 (en) | 2005-08-17 | 2007-02-22 | Altairnano, Inc. | Treatment of chronic renal failure and other conditions in domestic animals: compositions and methods |
| WO2007022466A2 (en) * | 2005-08-17 | 2007-02-22 | Altairnano, Inc. | Hyperphosphatemia in domestic animals: compositions and methods of treatment |
| US20070259052A1 (en) | 2006-05-05 | 2007-11-08 | Shire International Licensing B.V. | Assay for lanthanum hydroxycarbonate |
| CN101077338B (zh) * | 2006-05-24 | 2012-06-20 | 天津大学 | 纳米碳酸镧口腔崩解片及制备方法 |
| CN102714064B (zh) | 2009-11-06 | 2015-11-25 | 泰拉能源有限责任公司 | 核裂变行波反应堆及迁移燃料组件的系统 |
| AU2011252983C1 (en) | 2010-05-12 | 2015-02-19 | Unicycive Therapeutics, Inc. | Lanthanum carbonate hydroxide, lanthanum oxycarbonate and methods of their manufacture and use |
-
2011
- 2011-05-12 AU AU2011252983A patent/AU2011252983C1/en active Active
- 2011-05-12 RU RU2012146818/05A patent/RU2570007C2/ru active
- 2011-05-12 CN CN201180023076.0A patent/CN103037870B/zh active Active
- 2011-05-12 ES ES11721201T patent/ES2871021T3/es active Active
- 2011-05-12 EP EP21159393.4A patent/EP3848040A1/en active Pending
- 2011-05-12 JP JP2013510310A patent/JP5993368B2/ja active Active
- 2011-05-12 CA CA3224506A patent/CA3224506A1/en active Pending
- 2011-05-12 TW TW100116778A patent/TWI446916B/zh active
- 2011-05-12 WO PCT/US2011/036317 patent/WO2011143475A1/en not_active Ceased
- 2011-05-12 KR KR1020177030161A patent/KR101940207B1/ko active Active
- 2011-05-12 BR BR112012028629A patent/BR112012028629B8/pt active IP Right Grant
- 2011-05-12 KR KR1020127032038A patent/KR101830456B1/ko active Active
- 2011-05-12 MX MX2012013065A patent/MX350075B/es active IP Right Grant
- 2011-05-12 US US13/106,637 patent/US8961917B2/en active Active
- 2011-05-12 CA CA2798081A patent/CA2798081C/en active Active
- 2011-05-12 EP EP11721201.9A patent/EP2568989B1/en active Active
- 2011-05-13 AR ARP110101656A patent/AR081395A1/es active IP Right Grant
-
2012
- 2012-11-01 IL IL222824A patent/IL222824B/en active IP Right Grant
- 2012-12-10 ZA ZA2012/09322A patent/ZA201209322B/en unknown
-
2013
- 2013-12-12 US US14/104,663 patent/US10350240B2/en active Active
-
2016
- 2016-04-07 JP JP2016077533A patent/JP6397845B2/ja active Active
-
2018
- 2018-05-22 JP JP2018097513A patent/JP6938425B2/ja active Active
-
2019
- 2019-06-06 US US16/433,318 patent/US11406663B2/en active Active
-
2020
- 2020-01-10 AR ARP200100076A patent/AR117804A2/es unknown
-
2021
- 2021-09-01 JP JP2021142223A patent/JP7280318B2/ja active Active
-
2022
- 2022-07-11 US US17/861,413 patent/US20220347210A1/en not_active Abandoned
-
2025
- 2025-06-02 US US19/225,647 patent/US20250288608A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR081395A1 (es) | Hidroxido de carbonato de lantano oxicarbonato de lantano y metodos para su manufactura y uso | |
| AR091733A1 (es) | Proceso para producir minerales que contienen carbonato de calcio de superficie modificada | |
| PH12013501894A1 (en) | Human tissue factor antibody and uses thereof | |
| BR112014002036A2 (pt) | processo de fratura com água contendo material particulado | |
| EP4424408A3 (en) | Processes for preparing lithium hydroxide | |
| ECSP13013036A (es) | Alfa glucosidasa ácida modificada con procesamiento acelerado | |
| MX2019004378A (es) | Edulcorante de estevia altamente soluble. | |
| MY170302A (en) | Process for the preparation of an aqueous solution comprising at least one earth alkali hydrogen carbonate and its use | |
| AU341869S (en) | Ventilator | |
| AU327099S (en) | Gasket | |
| AR079821A1 (es) | Cepas y metodo para la produccion de metionina | |
| CL2014001202A1 (es) | Uso de por lo menos un polimero de tipo peine anionicamente cargado contra el deposito en suspencion acuosa que comprende material que contiene carbonato de calcio; suspension acuosa; metodo de produccion de dicha suspension que reduce deposito; y uso de dicha suspension. | |
| BR112015018249A2 (pt) | agente de tratamento, método de tratamento de uma chapa de aço, chapa de aço tratada e processo para a produção de uma chapa de aço tratada | |
| AR087483A1 (es) | Carbonato de calcio con tratamiento de superficie para la union y biorremediacion de composiciones que contienen hidrocarburos | |
| IN2014DN10712A (enExample) | ||
| BR112015013859A2 (pt) | corpo de carbono ferromagnético, processos para a produção de um corpo de carbono ferromagnético e de um corpo de carbono, uso de um corpo de carbono ferromagnético, e, catalisador | |
| CL2013000163A1 (es) | Proceso para la preparacion de material de carbonato de calcio que comprende proveer al menos un material que contenga carbonato de calcio, proveer al menos una sal de un acido graso c5-c28, tratar el material poniendolo en contacto con dicho acido graso y obtener dicho material tratado superficialmente; material de carbonato de calcio; y su uso en el control de material organico en un medio acuoso. | |
| GT201300256A (es) | Procesos para la elaboración de depsipéptidos macrocíclicos y nuevos intermediarios | |
| CL2010000918A1 (es) | Compuestos derivados de hidroxibencilo; uso de dichos compuestos para formar complejo con un cation; metodo para extraer un metal con dicho compuesto; el complejo en si; uso de dicho complejo como purificador de aire y como catalizador; y kit para descontaminar un liquido contaminado con un metal. | |
| BR112015008004A2 (pt) | processo de extração butadiene flexível | |
| AU341246S (en) | A urinal | |
| BR112012031053A2 (pt) | uso de 2-aminoetanol, e, método para aumentar o ph de uma suspensão aquosa. | |
| CL2011000273A1 (es) | Uso de un inhibidor de la enzima fosfohidrolasa de acido fosfatidico (pap) o combinacion de inhibidores, en que el inhibidor es d(+) propranolol, y la combinacion es mezcla racemica de propranolol o d(+) propranolol junto con desipramina, para preparar un medicamento util en el tratamiento del cancer. | |
| CL2012003645A1 (es) | Composicion farmaceutica de liberacion sostenida que comprende un compuesto derivado de metastina y un polimero de acido lactico; metodo de produccion; su uso para el tratamiento o prevencion del cancer. | |
| CL2010000713A1 (es) | Proceso de tratamiento preliminar de pilas de material mineral sometido a lixiviacion que comprende la disposicion de una capa mixta de cobertura permeable sobre la carpeta de base de las pilas, en donde dicha capa mixta esta compuesta por una mezcla de material de sulfuros de baja ley con oxidos. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HH | Correction or change in general | ||
| FG | Grant or registration |